There are millions of Americans with Type II diabetes and many of them take multiple daily injections of insulin, using two injection pens – one for mealtime insulin and one for insulin throughout the day. But studies have found that people with Type II diabetes are willing to skip insulin injections if they have to inject the drug in public.
“If you’re a Type II patient, you read it in magazines, you see it on TV, you see it in movies, you hear it from primary care doctors – [your diabetes] is your fault,” Valeritas (NSDQ:VLRX) CEO John Timberlake told Drug Delivery Business News.
The stigma surrounding Type II diabetes can make people feel uncomfortable taking their medications in a restaurant or at work, the chief executive explained. There are other reasons why a person might miss their insulin, like accidentally leaving their insulin pens at home or suffering from a debilitating fear of needles.
These are the kinds of patients Valeritas is hoping to help with its insulin delivery device, V-Go.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeritas takes on multiple daily insulin injections with wearable V-Go device appeared first on MassDevice.